SUMMARY. The quality of serum prolactin assays routinely performed by UK laboratories has been monitored in an external quality assessment scheme (EQAS) over a 10-year period, during which participation in the EQAS increased threefold, and considerable changes in methods and standardization were introduced. The all-laboratory mean was used as the sample target value, and proved to be stable and accurate. Overall between-laboratory agreement in the clinically important range improved from a geometric coefficient of variation (GCV) of 25% to 14%. This appears to reflect the increased use of kits in place of 'in-house' assays, the more widespread availability of international standards and the absence of any marked differences in bias between the commonly used methods. Published guidelines on the clinical interpretation of prolactin values should, therefore, be widely applicable. The EQAS data indicate that, in general, the quality of performance of prolactin assays is adequate for their clinical application.
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The measurement of serum prolactin is important in the investigation of amenorrhoea, infertility, and in the diagnosis and management of pituitary tumours. The analytical requirements to meet these applications have been recently reviewed.' Although the wide range of values found in health and disease does not demand assays of very high precision, guidelines for the interpretation of prolactin levels do require a close measure of between-laboratory agreement. The UK External Quality Assessment Scheme (UK EQAS) has monitored the quality of prolactin assays routinely performed by UK laboratories during the 1980s. The results are summarized in this report and their relevance to the clinical interpretation of prolactin levels is discussed.
MATERIALS AND METHODS

Operation of the scheme
Participation in the EQAS is voluntary and in the interests of confidentiality laboratories are referred to by code number only. The majority of serum pools distributed through the EQAS are from patients undergoing therapeutic venesection for polycythaemia rubra Vera; all are tested and proved negative for hepatitis B virus and antibodies to human immunodeficiency virus. In order to provide concentrations in the clinically important range, pools are supplemented with hyperprolactinaemic serum, or purified prolactin preparations; during the period reviewed these have included the First International Reference Preparation (IRP) 75/504,* interim standard 81 /541,' Second International Standard (IS) 83/562' and Third IS 84/500.' Since 1986, the pooled sera have been stabilized by the addition of sodium azide (o.05°/~ w/v) and filtered to sterility (0.2pm) under nitrogen at pressure (1 bar Figure I shows that p;irticipation in the schcmc trebled over the period o f review. In the e;irl> years the growth was mainly i n the usc of r;idioimniunoass;iy ( R I A ) kits uhilst in the l;i\t 3 years the grouth has been i n the iisc o f 1111-munometric assays (IMA). mainly using isotopic I;ihcls. A more detailed listing o f mcthods represented in the schcmc in Dcccnibcr I9SO is shoun in Figure 3 shows the trends in within-sample, between-laboratory agreement for all laboratories. As might be expected, agreement was less good at low concentrations. Since 1984 there has been a steady improvement in between-laboratory agreement, from about 25% to 14% at concentrations > 250mU/L, which is the range of greatest clinical interest. Figure 4 compares the cumulative bias of laboratories grouped according to the method used. The median bias was within 10% of the target for the majority of the methods. The exceptions were the Pharmacia DELFIA with a median bias of 15% (reflecting a temporary shift in standardization which has since been corrected) and the Amersham RIA and IDS OMNIA with median biases of -12%. Mean recovery within method groups was also generally satisfactory (Table 3) , although there appeared to be Figure 5 shows between-laboratory precision profiles for the major method groups. Betweenlaboratory agreement was best with the Serono MAIAclone and CHW RIA; it was generally worst among users of in-house RIA. The relatively high GCVs among users of the Pharmacia DELFIA were atypical of the performance of this kit and reflected a temporary change in standardization. 
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In an attempt to compare the robustness of methods when presented with sera containing hcterophilic antibodies, samples of serum pool with and without added human anti-mouse antibodies (HAMA) or sheep anti-mouse serum (SAMS) wcre issued in one distribution. Table 4 shows that, as expected, none of the RIA methods was affected, but that several of the 
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IMA gave falsely elevated results. The interference from HAMA was consistently less than that from SAMS and would not, in general, be sufficient to confuse the interpretation of results. The data indicate, however, that some prolactin IMA may be susceptible to this form of interference. *HAMA = human anti-mouse antibodies, 8pg/mL serum. Kindly provided by Dr G B Sivolapenko, Hammersmith Hospital, London, and isolated from the serum of a patient who had received radio-labelled MAb for imaging purposes. tSAMS = sheep anti-mouse serum, 0.05% added to human serum.
DISCUSSION
Before discussing the trends observed, it is important to consider the validity of the methods used in the EQAS. Human sera in liquid form were used throughout, avoiding the errors that can occur in reconstituting lyophilized samples. Although instability of liquid sera can be a hazard, there is evidence that prolactin in serum is stable for up to 2 weeks at room temperature. 6 The stability of the ALTM on repeated distribution of aliquots of the same pool over a period of several months was consistent with this.
As an added precaution. however, sterile filtration and addition of azide were instituted in 1986. Sample concentrations were chosen to lie in the range in which diagnostic decisions would be made, in order to ensure clinical relevance of the performance data. Demonstration of the accuracy of the target value is crucial to the validity of any EQAS.' Our approach to this has been to assess regularly the agreement between the calculated and found valucs of the ALTM in samples containing prolactin IS. In general, the accuracy of the ALTM has proved satisfactory. Such data from recovery experiments have their limitations in that they d o not demonstrate the accuracy of the ALTM in samples containing endogenous prolactin, and non-specific interference causing inaccuracy could pass undetected. In the absence of a reference method for serum prolactin, however, recovery experiments remain the best approach to validating the ALTM.
The most striking trend observed over the 10 year period reviewed is the steady improvement in overall between-laboratory agreement since 1984. This has occurred in spite of the assay being newly taken up by many laboratories and an increasing diversity of methods. There are probably several reasons for the improvement. First, international standards became available after a temporary lack of supply. Second, new participants in the EQAS generally employed kit rather than 'in-house' assays, and betweenlaboratory agreement is generally superior in the former (Fig. 5) . This probably reflects the use of common reagents and assay protocols, and is a feature of several EQAS for hormones4.' and for maternal serum alphafetoprotein.8 Third, the most commonly used methods showed relatively small differences in bias (Fig. 4) , even though they represented a wide range of assay types, using different monoclonal and polyclonal antibody combinations. This contrasts with our observations in the EQAS for LH, and to a lesser extent FSH, where diversification of assay methods has been associated with worsening overall between-laboratory agreernem5 This suggests that the antibody combinations used in the various prolactin assays, even using different assay designs and from different manufacturers, recognize similar molecular forms from the heterogeneous population present in serum.' Shifts in the bias of some methods were occasionally observed and were due to adjustments in standardization. Whether the availability of the EQAS in itself contributed towards improved performance is not known.
The EQAS also provided comparative data on other aspects of performance of the commonly used prolactin methods. Specificity with respect to the structurally related hormones, human placental lactogen and growth hormone, was good. However, interference from heterophilic antibodies, which bind to reagent antibodies and generate a false signal in sandwich-type IMA, did appear to be a potential danger (Table 4) . Although the effect of human anti-mouse antibodies (HAMA) was small, that from sheep anti-mouse serum (SAMS) was quite pronounced in some assays. Similar observations on the effect of SAMS have been made in the UK EQAS for FSH and LH.' Depending on their specificity and concentration, heterophilic antibodies cross-reacting with mouse immunoglobulins may show a different pattern of method interference from that demonstrated here using specific anti-mouse IgG; these data serve, accordingly, to illustrate the potential for this form of interference. The prevalence of interfering antibodies has been estimated to be as high as 40%,' and it should be noted that interference from HAMA will be an increasing hazard with the more widespread use of labelled murine monoclonal antibodies for imaging and treatment. Further studies to delineate more clearly the seriousness of interference from heterophilic antibodies in routinely performed assays are clearly warranted.
The clinical interpretation of serum prolactin levels is greatly assisted by the availability of guidelines indicating the range of values found in the various physiological, pharmacological and pathological causes of hyperprolactinaemia.' Further guidance on the use of prolactin levels in patients with large tumours, to discriminate between those with non-functioning tumours and stalk compression, and those with prolactinoma, has also been proposed.'" The validity of these guidelines for general use is clearly depen-London ECIA 7BE, UK dent on the achievement of good betweenlaboratory agreement, which in turn depends upon the absence of significant method bias. The data presented here indicate that progress has been made towards achieving these requirements. As an illustration, in 1984 the spread of results across UK laboratories (2.5th to 97.5th percentile) on a sample of 700 mU/L would have been 450 to 1090 mU/L, whereas the corresponding spread in 1989 was 540 to 910mU/L.
Progress in assay for prolactin, from its identification 20 years ago to its wide-scale and reliable measurement on a routine basis in clinical laboratories, has indeed been rapid.
